Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7901543 | 0.88 | LMNA (0.33) | LMNAPTGS2GPBAR1MEN1GAA | |
| SCHEMBL12545589 | 0.82 | HTT (0.31) | — | |
| SCHEMBL17244584 | 0.79 | MEN1 (0.45) | LMNAMEN1GAAKMT2A | |
| SCHEMBL12545279 | 0.75 | LMNA (0.33) | LMNAMEN1GAAKMT2A | |
| SCHEMBL16301784 | 0.64 | L3MBTL1 (0.39) | LMNAPTGS2GAA | |
| SCHEMBL9392519 | 0.62 | PTGS1 (0.48) | LMNAMEN1GAAKMT2A | |
| SCHEMBL5764953 | 0.62 | POLB (0.44) | GAAKMT2A | |
| Hydrochloric Acid SCHEMBL8377423 | 0.60 | PTGS1 (0.43) | LMNAMEN1GAAKMT2A | |
| SCHEMBL31327214 | 0.60 | MKNK2 (0.39) | LMNAGAAKMT2A | |
| SCHEMBL6612159 | 0.60 | POLB (0.46) | GPBAR1MEN1GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110135650-A1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | MERCK SHARP & DOHME LLC | 2011-06-09 | — | — | US | disclosed |
| WO-2010065717-A1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110135650-A1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | SERPINC1, F9, F8 | LMNA 95/4885PTGS2 2450/4885GPBAR1 3877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.